☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Sandoz
Sandoz Reports the US FDA’s Approval of Wyost and Jubbonti (Biosimilar, Denosumab)
March 6, 2024
Sandoz’s Jubbonti (biosimilar, denosumab) Receives Health Canada’s Approval for the Treatment of Osteoporosis
February 20, 2024
Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany
January 31, 2024
Sandoz Introduces High-Concentration Formulation of Hyrimoz in Europe
November 21, 2023
Sandoz Receives the EMA’s CHMP Positive Opinion of Biosimilar Trastuzumab for Breast and Gastric Cancer
October 10, 2023
Sandoz Receives EC’s Marketing Authorization for Biosimilar Tyruko to Treat Multiple Sclerosis
September 26, 2023
Load more...
Back to Home